Lyra Therapeutics Toekomstige groei
Future criteriumcontroles 2/6
Lyra Therapeutics is forecast to grow earnings and revenue by 20.5% and 58.8% per annum respectively while EPS is expected to grow by 32.9% per annum.
Belangrijke informatie
20.5%
Groei van de winst
32.9%
Groei van de winst per aandeel
| Pharmaceuticals winstgroei | 23.7% |
| Inkomstengroei | 58.8% |
| Toekomstig rendement op eigen vermogen | n/a |
| Dekking van analisten | Low |
| Laatst bijgewerkt | 10 Sep 2024 |
Recente toekomstige groei-updates
Recent updates
Will Lyra Therapeutics (NASDAQ:LYRA) Spend Its Cash Wisely?
Jan 25
We Think Lyra Therapeutics (NASDAQ:LYRA) Needs To Drive Business Growth Carefully
Sep 10Is Lyra Therapeutics (NASDAQ:LYRA) In A Good Position To Deliver On Growth Plans?
Mar 12Lyra Therapeutics appoints Nieman as Chief Medical Officer
Jul 05Lyra Therapeutics: Progress In The Clinic
May 18A First Look At Lyra Therapeutics
Apr 21Is Lyra Therapeutics (NASDAQ:LYRA) In A Good Position To Deliver On Growth Plans?
Mar 30Is Lyra Therapeutics (NASDAQ:LYRA) In A Good Position To Invest In Growth?
Dec 14We Think Lyra Therapeutics (NASDAQ:LYRA) Can Afford To Drive Business Growth
Aug 28We're Not Very Worried About Lyra Therapeutics' (NASDAQ:LYRA) Cash Burn Rate
May 04How Many Lyra Therapeutics, Inc. (NASDAQ:LYRA) Shares Do Institutions Own?
Mar 05Companies Like Lyra Therapeutics (NASDAQ:LYRA) Are In A Position To Invest In Growth
Jan 11
Lyra Therapeutics down 19% underwhelming data from lead program
Dec 07Lyra Therapeutics: An Intriguing Risk/Reward Proposition Tackling Chronic Rhinosinusitis
Nov 24Winst- en omzetgroeiprognoses
| Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
|---|---|---|---|---|---|
| 12/31/2026 | 10 | -65 | -60 | -45 | 3 |
| 12/31/2025 | 1 | -67 | -86 | -57 | 4 |
| 12/31/2024 | 2 | -90 | -78 | 23 | 4 |
| 6/30/2024 | 2 | -101 | -79 | -76 | N/A |
| 3/31/2024 | 2 | -69 | -73 | -70 | N/A |
| 12/31/2023 | 2 | -63 | -64 | -63 | N/A |
| 9/30/2023 | 1 | -62 | -57 | -56 | N/A |
| 6/30/2023 | 1 | -61 | -53 | -53 | N/A |
| 3/31/2023 | 1 | -60 | -47 | -47 | N/A |
| 12/31/2022 | 1 | -55 | -44 | -43 | N/A |
| 9/30/2022 | 2 | -55 | -44 | -43 | N/A |
| 6/30/2022 | 1 | -51 | -44 | -42 | N/A |
| 3/31/2022 | 1 | -48 | -32 | -30 | N/A |
| 12/31/2021 | 0 | -44 | -29 | -26 | N/A |
| 9/30/2021 | 0 | -37 | -24 | -20 | N/A |
| 6/30/2021 | N/A | -32 | -17 | -14 | N/A |
| 3/31/2021 | N/A | -26 | -28 | -25 | N/A |
| 12/31/2020 | N/A | -22 | -23 | -21 | N/A |
| 9/30/2020 | N/A | -20 | -20 | -19 | N/A |
| 6/30/2020 | N/A | -18 | -19 | -19 | N/A |
| 3/31/2020 | N/A | -17 | -15 | -15 | N/A |
| 12/31/2019 | N/A | -17 | -14 | -14 | N/A |
| 12/31/2018 | 1 | -6 | -7 | -7 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: LYRA is forecast to remain unprofitable over the next 3 years.
Winst versus markt: LYRA is forecast to remain unprofitable over the next 3 years.
Hoge groeiwinsten: LYRA is forecast to remain unprofitable over the next 3 years.
Omzet versus markt: LYRA's revenue (58.8% per year) is forecast to grow faster than the US market (8.9% per year).
Hoge groei-inkomsten: LYRA's revenue (58.8% per year) is forecast to grow faster than 20% per year.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Insufficient data to determine if LYRA's Return on Equity is forecast to be high in 3 years time